<?xml version='1.0' encoding='utf-8'?>
<document id="22527351"><sentence text="The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects."><entity charOffset="14-25" id="DDI-PubMed.22527351.s1.e0" text="lersivirine" /><entity charOffset="79-88" id="DDI-PubMed.22527351.s1.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.22527351.s1.e0" e2="DDI-PubMed.22527351.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22527351.s1.e0" e2="DDI-PubMed.22527351.s1.e1" /></sentence><sentence text="Lersivirine is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with a unique resistance profile that exhibits potent antiretroviral activity against wild-type human immunodeficiency virus and clinically relevant NNRTI-resistant strains"><entity charOffset="0-11" id="DDI-PubMed.22527351.s2.e0" text="Lersivirine" /></sentence><sentence text=" Results from in vitro and in vivo investigations suggest that lersivirine is a cytochrome P450 (CYP3A4) inducer that is metabolized by CYP3A4 and uridine diphosphate glucuronosyltransferase (UGT) 2B7"><entity charOffset="63-74" id="DDI-PubMed.22527351.s3.e0" text="lersivirine" /><entity charOffset="147-166" id="DDI-PubMed.22527351.s3.e1" text="uridine diphosphate" /><pair ddi="false" e1="DDI-PubMed.22527351.s3.e0" e2="DDI-PubMed.22527351.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22527351.s3.e0" e2="DDI-PubMed.22527351.s3.e1" /></sentence><sentence text=" In order to formally assess the effects of lersivirine on CYP3A4 metabolism and/or glucuronidation, we performed studies aimed at investigating the effects of lersivirine co-administration on the pharmacokinetics (PK) of midazolam, ethinylestradiol and levonorgestrel"><entity charOffset="44-55" id="DDI-PubMed.22527351.s4.e0" text="lersivirine" /><entity charOffset="160-171" id="DDI-PubMed.22527351.s4.e1" text="lersivirine" /><entity charOffset="222-231" id="DDI-PubMed.22527351.s4.e2" text="midazolam" /><entity charOffset="233-249" id="DDI-PubMed.22527351.s4.e3" text="ethinylestradiol" /><entity charOffset="254-268" id="DDI-PubMed.22527351.s4.e4" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.22527351.s4.e0" e2="DDI-PubMed.22527351.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22527351.s4.e0" e2="DDI-PubMed.22527351.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22527351.s4.e0" e2="DDI-PubMed.22527351.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22527351.s4.e0" e2="DDI-PubMed.22527351.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22527351.s4.e0" e2="DDI-PubMed.22527351.s4.e4" /><pair ddi="false" e1="DDI-PubMed.22527351.s4.e1" e2="DDI-PubMed.22527351.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22527351.s4.e1" e2="DDI-PubMed.22527351.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22527351.s4.e1" e2="DDI-PubMed.22527351.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22527351.s4.e1" e2="DDI-PubMed.22527351.s4.e4" /><pair ddi="false" e1="DDI-PubMed.22527351.s4.e2" e2="DDI-PubMed.22527351.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22527351.s4.e2" e2="DDI-PubMed.22527351.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22527351.s4.e2" e2="DDI-PubMed.22527351.s4.e4" /><pair ddi="false" e1="DDI-PubMed.22527351.s4.e3" e2="DDI-PubMed.22527351.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22527351.s4.e3" e2="DDI-PubMed.22527351.s4.e4" /></sentence><sentence text="" /><sentence text="Two drug-drug interaction studies were performed" /><sentence text=" Healthy subjects were co-administered (1) single dose midazolam, a prototypical CYP3A4 substrate, followed by 14 days of lersivirine twice daily with single dose midazolam on the final day of lersivirine dosing or (2) 10 days of once-daily (QD) lersivirine and QD oral contraceptives (OCs; ethinylestradiol and levonorgestrel), substrates for CYP3A4, UGT2B7, and/or P-glycoprotein"><entity charOffset="55-64" id="DDI-PubMed.22527351.s7.e0" text="midazolam" /><entity charOffset="122-133" id="DDI-PubMed.22527351.s7.e1" text="lersivirine" /><entity charOffset="163-172" id="DDI-PubMed.22527351.s7.e2" text="midazolam" /><entity charOffset="193-204" id="DDI-PubMed.22527351.s7.e3" text="lersivirine" /><entity charOffset="246-257" id="DDI-PubMed.22527351.s7.e4" text="lersivirine" /><entity charOffset="291-307" id="DDI-PubMed.22527351.s7.e5" text="ethinylestradiol" /><entity charOffset="312-326" id="DDI-PubMed.22527351.s7.e6" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e0" e2="DDI-PubMed.22527351.s7.e0" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e0" e2="DDI-PubMed.22527351.s7.e1" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e0" e2="DDI-PubMed.22527351.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e0" e2="DDI-PubMed.22527351.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e0" e2="DDI-PubMed.22527351.s7.e4" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e0" e2="DDI-PubMed.22527351.s7.e5" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e0" e2="DDI-PubMed.22527351.s7.e6" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e1" e2="DDI-PubMed.22527351.s7.e1" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e1" e2="DDI-PubMed.22527351.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e1" e2="DDI-PubMed.22527351.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e1" e2="DDI-PubMed.22527351.s7.e4" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e1" e2="DDI-PubMed.22527351.s7.e5" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e1" e2="DDI-PubMed.22527351.s7.e6" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e2" e2="DDI-PubMed.22527351.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e2" e2="DDI-PubMed.22527351.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e2" e2="DDI-PubMed.22527351.s7.e4" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e2" e2="DDI-PubMed.22527351.s7.e5" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e2" e2="DDI-PubMed.22527351.s7.e6" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e3" e2="DDI-PubMed.22527351.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e3" e2="DDI-PubMed.22527351.s7.e4" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e3" e2="DDI-PubMed.22527351.s7.e5" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e3" e2="DDI-PubMed.22527351.s7.e6" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e4" e2="DDI-PubMed.22527351.s7.e4" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e4" e2="DDI-PubMed.22527351.s7.e5" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e4" e2="DDI-PubMed.22527351.s7.e6" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e5" e2="DDI-PubMed.22527351.s7.e5" /><pair ddi="false" e1="DDI-PubMed.22527351.s7.e5" e2="DDI-PubMed.22527351.s7.e6" /></sentence><sentence text=" The effects of co-administration on the PK parameters of midazolam and OCs were assessed"><entity charOffset="58-67" id="DDI-PubMed.22527351.s8.e0" text="midazolam" /></sentence><sentence text="" /><sentence text="At clinically relevant lersivirine doses (500-1,000 mg total daily dose), the mean plasma exposure of midazolam was reduced in a dose-dependent manner by 20-36 %"><entity charOffset="23-34" id="DDI-PubMed.22527351.s10.e0" text="lersivirine" /><entity charOffset="102-111" id="DDI-PubMed.22527351.s10.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.22527351.s10.e0" e2="DDI-PubMed.22527351.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22527351.s10.e0" e2="DDI-PubMed.22527351.s10.e1" /></sentence><sentence text=" Co-administration of lersivirine 1,000 mg QD with OCs had minor PK effects, increasing ethinylestradiol exposure by 10 % and reducing levonorgestrel exposure by 13 %"><entity charOffset="22-33" id="DDI-PubMed.22527351.s11.e0" text="lersivirine" /><entity charOffset="88-104" id="DDI-PubMed.22527351.s11.e1" text="ethinylestradiol" /><entity charOffset="135-149" id="DDI-PubMed.22527351.s11.e2" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.22527351.s11.e0" e2="DDI-PubMed.22527351.s11.e0" /><pair ddi="false" e1="DDI-PubMed.22527351.s11.e0" e2="DDI-PubMed.22527351.s11.e1" /><pair ddi="false" e1="DDI-PubMed.22527351.s11.e0" e2="DDI-PubMed.22527351.s11.e2" /><pair ddi="false" e1="DDI-PubMed.22527351.s11.e1" e2="DDI-PubMed.22527351.s11.e1" /><pair ddi="false" e1="DDI-PubMed.22527351.s11.e1" e2="DDI-PubMed.22527351.s11.e2" /></sentence><sentence text="" /><sentence text="These data further support previous observations that lersivirine is a weak CYP3A4 inducer, a weak inhibitor of glucuronidation, and a P-glycoprotein inhibitor"><entity charOffset="54-65" id="DDI-PubMed.22527351.s13.e0" text="lersivirine" /></sentence><sentence text=" In both studies, lersivirine appeared to have a good safety and tolerability profile" /><sentence text="" /></document>